Inhibitory superagonistic antibodies as novel therapeutics by Donat, RF

Heterotypic interactions drive antibody synergy against a malaria vaccine candidate by Ragotte, RJ, Pulido, D, Lias, AM, Quinkert, D, Alanine, DGW, Jamwal, A, Davies, H, Nacer, A, Lowe, ED, Grime, GW, Illingworth, JJ, Donat, RF, Garman, EF, Bowyer, PW, Higgins, MK, Draper, SJ

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient by Zhou, D, Duyvesteyn, HME, Chen, C-P, Huang, C-G, Chen, T-H, Shih, S-R, Lin, Y-C, Cheng, C-Y, Cheng, S-H, Huang, Y-C, Lin, T-Y, Ma, C, Huo, J, Carrique, L, Malinauskas, T, Ruza, RR, Shah, PNM, Tan, TK, Rijal, P, Donat, RF, Godwin, K, Buttigieg, KR, Tree, JA, Radecke, J, Paterson, NG, Supasa, P, Mongkolsapaya, J, Screaton, GR, Carroll, MW, Gilbert-Jaramillo, J, Knight, ML, James, W, Owens, RJ, Naismith, JH, Townsend, AR, Fry, EE, Zhao, Y, Ren, J, Stuart, DI, Huang, K-YA